The neem story

Neem Biotech is a unique, rapidly growing and fully integrated R&D life sciences organisation. As a leader in the development of anti-infectives, we work with a range of natural resources to develop multiple strategies to bring antimicrobial products to market.

Our focus is on impact and original thinking. Disrupting the old to generate new states of equilibrium for existing healthcare challenges. These are amongst our core values.

We began our operations in 1998 as a niche contract research company. Since then, our organisation and its talented scientific team have discovered unique ways to extract the best that nature has to offer – from marine and plant sources – and develop those bioactive compounds into platform technologies that can be used to treat human, animal and plant infections in areas of high unmet medical need and rare diseases.

Our first patent was granted in 2000 for the process of extracting allicin from garlic. Over the years we have grown and became a wholly owned subsidiary of Zaluvida Holdings Pte Ltd in 2012. In 2015 we moved headquarters to new, 15,000ft2 purpose-built facilities in Abertillery, South Wales where we have been able to bring to life our drug development pipeline schedule.

The neem story

Neem Biotech is a unique, rapidly growing and fully integrated R&D life sciences organisation. As a leader in the development of anti-infectives, we work with a range of natural resources to develop multiple strategies to bring antimicrobial products to market.

Our focus is on impact and original thinking. Disrupting the old to generate new states of equilibrium for existing healthcare challenges. These are amongst our core values.

We began our operations in 1998 as a niche contract research company. Since then, our organisation and its talented scientific team have discovered unique ways to extract the best that nature has to offer – from marine and plant sources – and develop those bioactive compounds into platform technologies that can be used to treat human, animal and plant infections in areas of high unmet medical need and rare diseases.

Our first patent was granted in 2000 for the process of extracting allicin from garlic. Over the years we have grown and became a wholly owned subsidiary of Zaluvida Holdings Pte Ltd in 2012. In 2015 we moved headquarters to new, 15,000ft2 purpose-built facilities in Abertillery, South Wales where we have been able to bring to life our drug development pipeline schedule.